Format

Send to

Choose Destination
Thromb Haemost. 2008 May;99(5):819-29. doi: 10.1160/TH07-11-0693.

The direct thrombin inhibitor hirudin.

Author information

1
Institute for Immunology and Transfusion Medicine, Ernst-Moritz-Arndt University Greifswald, Sauerbruchstrasse, 17489 Greifswald, Germany. greinach@uni-greifswald.de

Abstract

This review discusses the pharmacology and clinical applications of hirudin, a bivalent direct thrombin inhibitor (DTI). Besides the current major indication for hirudin--anticoagulation of patients with heparin-induced thrombocytopenia (HIT)--the experience with hirudin in other indications, especially acute coronary syndromes, are briefly presented. Hirudins have been formally studied prior to their regulatory approval; however, important information on their side effects and relevant preventative measures only became available later. Therefore, current recommendations and dosing schedules for hirudin differ considerably from the information given in the package inserts. Drawbacks of hirudin and important precautions for avoiding potential adverse effects are discussed in detail in the third part of this review.

PMID:
18449411
DOI:
10.1160/TH07-11-0693
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Georg Thieme Verlag Stuttgart, New York
Loading ...
Support Center